Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …
practice, largely reflecting their ability to inhibit specific molecular alterations that are …
The renaissance of cyclin dependent kinase inhibitors
T Ettl, D Schulz, RJ Bauer - Cancers, 2022 - mdpi.com
Simple Summary This review provides an overview of the state of knowledge and general
understanding of CDK inhibitors currently under development or clinically approved, with a …
understanding of CDK inhibitors currently under development or clinically approved, with a …
Palbociclib induces senescence in melanoma and breast cancer cells and leads to additive growth arrest in combination with irradiation
Introduction Several kinase inhibitors (KI) bear the potential to act as radiosensitizers. Little
is known of the radiosensitizing effects of a wide range of other KI like palbociclib, which is …
is known of the radiosensitizing effects of a wide range of other KI like palbociclib, which is …
Targeting DNA damage repair for immune checkpoint inhibition: mechanisms and potential clinical applications
W Sun, Q Zhang, R Wang, Y Li, Y Sun, L Yang - Frontiers in Oncology, 2021 - frontiersin.org
DNA damage repair (DDR) pathways play an essential role in maintaining genomic integrity.
DDR dysfunction leads to accumulated DNA damage, predisposition to cancer, and high …
DDR dysfunction leads to accumulated DNA damage, predisposition to cancer, and high …
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Y Yang, J Luo, X Chen, Z Yang, X Mei, J Ma… - Journal of Experimental …, 2020 - Springer
Recently, the focus of enhancing tumor radiosensitivity has shifted from chemotherapeutics
to targeted therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are a novel class …
to targeted therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are a novel class …
[HTML][HTML] CDK 4/6 inhibitors combined with radiotherapy: a review of literature
C Bosacki, W Bouleftour, S Sotton, A Vallard… - Clinical and translational …, 2021 - Elsevier
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and
abemaciclib were granted approval by the European Medicines Agency (EMA) between …
abemaciclib were granted approval by the European Medicines Agency (EMA) between …
Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo) radiotherapy of locally advanced head and neck squamous cell carcinoma
N Ngamphaiboon, A Chairoungdua, T Dajsakdipon… - Oral Oncology, 2023 - Elsevier
Chemoradiotherapy (CRT) remains the standard treatment for locally advanced head and
neck squamous cell carcinoma (LA-HNSCC), based on numerous randomized controlled …
neck squamous cell carcinoma (LA-HNSCC), based on numerous randomized controlled …
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients
AE Guerini, S Pedretti, E Salah, EL Simoncini… - Scientific Reports, 2020 - nature.com
Abstract Cyclin dependent kinases 4/6 (CDK4/6) inhibitors gained an essential role in the
treatment of metastatic breast cancer. Nevertheless, data regarding their use in combination …
treatment of metastatic breast cancer. Nevertheless, data regarding their use in combination …
Short-term CDK4/6 inhibition radiosensitizes estrogen receptor–positive breast cancers
AM Pesch, NH Hirsh, BC Chandler… - Clinical Cancer …, 2020 - AACR
Abstract Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved
progression-free survival for metastatic, estrogen receptor–positive (ER+) breast cancers …
progression-free survival for metastatic, estrogen receptor–positive (ER+) breast cancers …
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?
C Riess, N Irmscher, I Salewski, D Strüder… - Cancer and Metastasis …, 2021 - Springer
Cyclin-dependent kinases (CDK) control the cell cycle and play a crucial role in
oncogenesis. Pharmacologic inhibition of CDK has contributed to the recent clinical …
oncogenesis. Pharmacologic inhibition of CDK has contributed to the recent clinical …